WHAT IS CLAIMED IS:

1. A combination comprising:

   a. ibrutinib or a pharmaceutically acceptable salt thereof; and

   b. GA101 or a pharmaceutically acceptable salt thereof.

2. The combination according to claim 1, wherein ibrutinib is in an amount of about 300 mg/day to about 1000 mg/day.

3. The combination according to claim 1, wherein ibrutinib is in an amount of about 420 mg/day to about 840 mg/day.

4. The combination according to claim 1, wherein ibrutinib is in an amount of about 420 mg/day.

5. The combination according to any one of claims 1-4, wherein ibrutinib and GA101 are in a single or in separate dosage forms.

6. Use of

   (a) ibrutinib or a pharmaceutically acceptable salt thereof, and

   (b) GA101 or a pharmaceutically acceptable salt thereof

   in the manufacture of a medicament for the treatment of a hematological malignancy.

7. The use according to claim 6, wherein ibrutinib and GA101 are in a single or separate dosage forms.

8. The use according to claim 6 or claim 7, wherein the hematological malignancy is selected from leukemia, a lymphoproliferative disorder, and a myeloid disorder.

9. The use according to claim 6 or claim 7, wherein the hematological malignancy is a B-cell malignancy.

10. The use according to claim 6 or claim 7, wherein the hematological malignancy is chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

11. The use according to claim 6 or claim 7, wherein the hematological malignancy is mantle cell lymphoma.

12. The use according to claim 6 or claim 7, wherein the hematological malignancy is Waldenström's macroglobulinemia.

13. The use according to claim 6 or claim 7, wherein the hematological malignancy is acute myelogenous leukemia (AML).

14. The use according to claim 6 or claim 7, wherein the hematological malignancy is diffuse large B-cell lymphoma (DLBCL).

15. The use according to claim 6 or claim 7, wherein the hematological malignancy is follicular lymphoma (FL).

16. The use according to any one of claims 6-15, wherein the individual is identified as having an increased presence, expression, or level of expression of a biomarker selected from: CXCR4, Ki67, MDC, MIP-1β, CXCL13, CXCL17, IL-10, MIP-1α, CCL17, and CCL21.